<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p33" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_33{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_33{left:341px;bottom:30px;}
#t3_33{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_33{left:377px;bottom:30px;}
#t5_33{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_33{left:540px;bottom:30px;}
#t7_33{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_33{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_33{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_33{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_33{left:285px;bottom:827px;letter-spacing:-0.26px;}
#tc_33{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_33{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_33{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_33{left:1107px;bottom:47px;letter-spacing:0.36px;}
#tg_33{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_33{left:432px;bottom:777px;letter-spacing:0.39px;word-spacing:-0.22px;}
#ti_33{left:759px;bottom:784px;letter-spacing:-0.12px;}
#tj_33{left:36px;bottom:299px;}
#tk_33{left:46px;bottom:293px;letter-spacing:0.08px;word-spacing:-0.02px;}
#tl_33{left:346px;bottom:293px;letter-spacing:0.12px;}
#tm_33{left:375px;bottom:293px;letter-spacing:0.13px;}
#tn_33{left:449px;bottom:293px;}
#to_33{left:36px;bottom:282px;}
#tp_33{left:46px;bottom:276px;letter-spacing:0.11px;word-spacing:0.02px;}
#tq_33{left:36px;bottom:266px;}
#tr_33{left:46px;bottom:260px;letter-spacing:0.12px;word-spacing:0.01px;}
#ts_33{left:36px;bottom:249px;}
#tt_33{left:46px;bottom:243px;letter-spacing:0.12px;word-spacing:-0.03px;}
#tu_33{left:556px;bottom:243px;}
#tv_33{left:36px;bottom:232px;}
#tw_33{left:46px;bottom:226px;letter-spacing:0.12px;word-spacing:0.01px;}
#tx_33{left:45px;bottom:209px;letter-spacing:0.14px;}
#ty_33{left:36px;bottom:198px;}
#tz_33{left:46px;bottom:192px;letter-spacing:0.11px;word-spacing:-0.04px;}
#t10_33{left:45px;bottom:176px;letter-spacing:0.14px;}
#t11_33{left:36px;bottom:165px;letter-spacing:0.08px;}
#t12_33{left:53px;bottom:159px;letter-spacing:0.1px;word-spacing:-0.03px;}
#t13_33{left:45px;bottom:142px;letter-spacing:0.12px;word-spacing:0.01px;}
#t14_33{left:36px;bottom:131px;letter-spacing:-0.83px;}
#t15_33{left:52px;bottom:125px;letter-spacing:0.11px;}
#t16_33{left:45px;bottom:108px;letter-spacing:0.11px;word-spacing:0.01px;}
#t17_33{left:36px;bottom:746px;letter-spacing:-0.24px;}
#t18_33{left:36px;bottom:728px;letter-spacing:-0.1px;}
#t19_33{left:351px;bottom:735px;letter-spacing:-0.27px;}
#t1a_33{left:36px;bottom:709px;}
#t1b_33{left:47px;bottom:709px;letter-spacing:-0.09px;}
#t1c_33{left:36px;bottom:691px;letter-spacing:-0.1px;}
#t1d_33{left:41px;bottom:673px;}
#t1e_33{left:58px;bottom:673px;letter-spacing:-0.09px;word-spacing:-0.05px;}
#t1f_33{left:721px;bottom:673px;letter-spacing:-0.12px;}
#t1g_33{left:783px;bottom:673px;}
#t1h_33{left:63px;bottom:654px;}
#t1i_33{left:76px;bottom:654px;letter-spacing:-0.09px;}
#t1j_33{left:41px;bottom:636px;}
#t1k_33{left:58px;bottom:636px;letter-spacing:-0.09px;}
#t1l_33{left:63px;bottom:618px;}
#t1m_33{left:76px;bottom:618px;letter-spacing:-0.09px;}
#t1n_33{left:547px;bottom:625px;}
#t1o_33{left:36px;bottom:563px;letter-spacing:-0.09px;}
#t1p_33{left:134px;bottom:563px;letter-spacing:-0.08px;}
#t1q_33{left:224px;bottom:563px;letter-spacing:-0.1px;}
#t1r_33{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_33{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_33{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_33{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_33{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_33{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_33{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_33{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.s7_33{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s8_33{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s9_33{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.sa_33{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sb_33{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sc_33{font-size:17px;font-family:Webdings_k6;color:#000;}
.sd_33{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.se_33{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.sf_33{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts33" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg33Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg33" style="-webkit-user-select: none;"><object width="1210" height="935" data="33/33.svg" type="image/svg+xml" id="pdf33" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_33" class="t s0_33">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_33" class="t s1_33">® </span>
<span id="t3_33" class="t s0_33">(NCCN </span>
<span id="t4_33" class="t s1_33">® </span>
<span id="t5_33" class="t s0_33">), All rights reserved. NCCN Guidelines </span>
<span id="t6_33" class="t s1_33">® </span>
<span id="t7_33" class="t s0_33">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_33" class="t s2_33">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_33" class="t s2_33">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_33" class="t s3_33">NCCN Guidelines Version 4.2024 </span>
<span id="tb_33" class="t s3_33">Cancer of the Hypopharynx </span>
<span id="tc_33" class="t s4_33">NCCN Guidelines Index </span>
<span id="td_33" class="t s4_33">Table of Contents </span>
<span id="te_33" class="t s4_33">Discussion </span>
<span id="tf_33" class="t s5_33">HYPO-A </span>
<span id="tg_33" class="t s5_33">2 OF 2 </span>
<span id="th_33" class="t s5_33">PRINCIPLES OF RADIATION THERAPY </span>
<span id="ti_33" class="t s6_33">1,2 </span>
<span id="tj_33" class="t s7_33">1 </span>
<span id="tk_33" class="t s8_33">Principles of Radiation Techniques (RAD-A) </span><span id="tl_33" class="t s9_33">and </span><span id="tm_33" class="t s8_33">Discussion</span><span id="tn_33" class="t s9_33">. </span>
<span id="to_33" class="t s7_33">2 </span>
<span id="tp_33" class="t s9_33">Particular attention to speech and swallowing is needed during therapy. </span>
<span id="tq_33" class="t s7_33">5 </span>
<span id="tr_33" class="t s9_33">Suggest 44–50 Gy in 3D-CRT and sequentially planned IMRT or 54–63 Gy with IMRT dose painting technique (dependent on dose per fraction). </span>
<span id="ts_33" class="t s7_33">6 </span>
<span id="tt_33" class="t s8_33">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="tu_33" class="t s9_33">. </span>
<span id="tv_33" class="t s7_33">8 </span>
<span id="tw_33" class="t sa_33">Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med </span>
<span id="tx_33" class="t s9_33">2004;350:1945-1952. </span>
<span id="ty_33" class="t s7_33">9 </span>
<span id="tz_33" class="t s9_33">Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. </span>
<span id="t10_33" class="t s9_33">N Engl J Med 2004;350:1937-1944. </span>
<span id="t11_33" class="t s7_33">10 </span>
<span id="t12_33" class="t s9_33">Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation </span>
<span id="t13_33" class="t s9_33">plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 2005;27:843-850. </span>
<span id="t14_33" class="t s7_33">11 </span>
<span id="t15_33" class="t s9_33">Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy </span>
<span id="t16_33" class="t s9_33">in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2012;84:1198-1205. </span>
<span id="t17_33" class="t s5_33">POSTOPERATIVE: </span>
<span id="t18_33" class="t s5_33">RT or Concurrent Systemic Therapy/RT </span>
<span id="t19_33" class="t s6_33">6,8-11 </span>
<span id="t1a_33" class="t s5_33">• </span><span id="t1b_33" class="t sb_33">Preferred interval between resection and postoperative RT is ≤6 weeks. </span>
<span id="t1c_33" class="t s5_33">• PTV </span>
<span id="t1d_33" class="t sc_33"></span><span id="t1e_33" class="t s5_33">High risk: Adverse pathologic features such as positive margins (see footnote j on </span><span id="t1f_33" class="t sd_33">HYPO-3</span><span id="t1g_33" class="t s5_33">) </span>
<span id="t1h_33" class="t se_33">◊ </span><span id="t1i_33" class="t s5_33">60–66 Gy (2.0 Gy/fraction; daily Monday–Friday) in 6–6.5 weeks </span>
<span id="t1j_33" class="t sc_33"></span><span id="t1k_33" class="t s5_33">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t1l_33" class="t se_33">◊ </span><span id="t1m_33" class="t s5_33">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t1n_33" class="t s6_33">5 </span>
<span id="t1o_33" class="t s5_33">Either IMRT </span><span id="t1p_33" class="t s5_33">(preferred) </span><span id="t1q_33" class="t s5_33">or 3D-CRT is recommended. </span>
<span id="t1r_33" class="t sf_33">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
